Multiple Myeloma Therapy Market Set For “Robust” Annual Growth
The multiple myeloma drug therapy market will experience robust growth averaging 5.6% annually from 2010 to 2020 in seven of the world’s major markets, according to new projections. Growth in these markets – US, Italy, Spain, UK, France, Germany and Japan – will be driven by additional penetration of Celgene’s Revlimid (lenalidomide) into the first-line